Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long‐term treatment with an aldose reductase inhibitor, epalrestat

Abstract

Our results suggest that epalrestat, an aldose reductase inhibitor, will provide a clinically significant means of preventing and treating diabetic neuropathy if used in appropriate patients.